French biotech Abivax SA (OTCPK:AAVXF) announces that Brazil’s Health Regulatory Agency has signed off on its Phase 2/3 clinical trial, MiR-AGE,
evaluating lead candidate ABX464 for the treatment of inflammation and
prevention of acute respiratory failure in COVID-19 patients.
The study was previously OK’d in France and Germany.
The primary endpoint is the proportion of patients
with no invasive or non-invasive mechanical ventilation (excluding
supplemental oxygen) and who are alive at the end of the 28-day
treatment period.
The estimated primary completion date is December.
ABX464 is
an orally available small molecule that, it says, exhibits an antiviral
effect, an anti-inflammatory effect and tissue repair properties
preventing longer-term pulmonary problems.
https://seekingalpha.com/news/3585125-study-of-abivax-covidminus-19-drug-expanded-to-brazil
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.